Compare Hewlett Packard Enterprise Co (HPE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Repligen Corporation Common Stock — how do they compare? Hewlett Packard Enterprise Co trades at $60.92 (market cap $83.78B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Hewlett Packard Enterprise Co is far larger — about 7.4× Repligen Corporation Common Stock's market cap, and Hewlett Packard Enterprise Co pays a 0.9% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 34 Days and Repligen Corporation Common Stock for 0 Days on average.
| HPE | RGEN | |
|---|---|---|
Market Cap | $83.78B | $11.31B |
Volume | 21,753,370 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $73.46 | $194.57 |
52-Week Low | $20.01 | $102.87 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $97.80B | $11.20B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE stock trades at $68.80, down 2.13% today but remains near recent highs driven by strong AI infrastructure demand. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS of $1.11 significantly exceeding the $0.932 forecast. Technical indicators show a bullish trend with support at $68 and resistance at $72, while valuation metrics include a P/E of 35.47 and P/S of 2.32. Recent news highlights a $1.2 billion AI server order from Vultr and raised revenue guidance for 2026.
HPE presents a compelling growth story fueled by AI infrastructure expansion, with analyst consensus pointing to 45% buy ratings and a $70 price target. Key risks include elevated valuation multiples and execution challenges in integrating recent acquisitions. The stock's 160% year-over-year rally suggests much optimism is priced in, requiring continued strong execution to justify further upside.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
